Insight Molecular Diagnostics (IMDX) Q3 2024 earnings summary

Executive summary

• Achieved significant progress in democratizing transplant testing with technology deployed on three continents, major transplant centers signed, and a disruptive kit-based model empowering local labs over central lab models.

• Strategic partnerships, notably with Bio-Rad, expanded reach and credibility, including an equity investment and exclusive commercialization rights outside the US.

• VitaGraft Kidney received Medicare reimbursement in August 2023 and was validated in a May 2024 NEJM publication; GraftAssure and DetermaIO pipelines are advancing in transplant and oncology markets.

• Commercial launch of GraftAssure research-use test is progressing, with agreements at major U.S. and European transplant centers and a focus on building a customer base ahead of FDA clearance.

• Management has concluded that substantial doubt exists about the company’s ability to continue as a going concern for at least one year from the date of the report.

Financial highlights

• Q3 2024 net revenue was $115,000, down from $429,000 in Q3 2023, with gross profit of $50,000 and operating expenses of $13.6 million, including a $7.1 million non-cash contingent consideration expense.

• Net loss for Q3 2024 was $13.5 million, compared to $6.5 million in Q3 2023; cash and cash equivalents at September 30, 2024, were $3.4 million.

• Raised $10.2 million gross ($9.4 million net) in an October 2024 private placement, and $9.9 million net in April 2024, with Bio-Rad participating.

• Gross margin for Q3 2024 was 43%; net loss per share was $0.98, with 13.7 million weighted average shares outstanding.

• Accumulated deficit as of September 30, 2024, was $317 million.

Outlook and guidance

• On track to have more than 20 transplant centers running GraftAssure by end of 2025, each representing potential high-margin annual revenue.

• FDA review of clinical validation plan for transplant diagnostics expected by December 2024, with final data submission mid-2025 and FDA decision targeted for late 2025.

• No meaningful transplant test revenue expected until FDA-cleared IVD launch; significant revenue growth anticipated post-clearance and reimbursement.

• Management expects continued operating losses and negative cash flows, with plans to seek additional equity financing.

• Ongoing expansion into oncology diagnostics, with CMS submission for Determa CNI expected Q4 2024.